a public good project by the
Synthesis
Company
of California

© 2026

Semiglazov Vf | doi.page

0 works0 citations0 h-index

Semiglazov Vf

Institute of Oncology NN Petrov(RU)

Publications by Year

Research Areas

Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Estrogen and related hormone effects

Most-Cited Works

→ Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis(2014)4,585 cited
→ Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013(2013)3,672 cited
→ Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial(2011)2,312 cited
→ Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015(2015)1,820 cited
→ Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial(2012)1,303 cited

→ Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort(2010)

1,254 cited

→ De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017(2017)1,245 cited

→ Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study(2013)992 cited

→ Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study(2020)865 cited

→ 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial(2016)852 cited